John Connolly

John Connolly is an accomplished leader in immunology and cancer research, currently serving as Interim CEO at 3T Biosciences and Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy. With extensive experience as Senior Principal Investigator and Director for Translational Immunology at the Institute of Molecular and Cell Biology, and a Clinical Scientist at KK Women's & Children's Hospital, Connolly has made significant contributions to the understanding of immune responses and treatment strategies. As an educator, Connolly holds adjunct associate professor positions at Baylor University and the National University of Singapore, while previously leading research initiatives at Tessa Therapeutics and A*STAR Biomedical Research Council. John Connolly earned a Ph.D. in Biochemistry from the Geisel School of Medicine at Dartmouth and a B.Sc. in Chemistry and Biology from Framingham State University.